Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.

Thomas BartlAnita AlbertsSofia-Christina PapadopoulosAndrea WolfLeonhard MuellauerGerda HofstetterChristoph GrimmDan Cacsire Castillo-Tong

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

A sub-group of mucinous ovarian cancers appear to demonstrate a pro-immunogenic tumor environment with high PD-L1 expression, decreased ARID1A expression, and characteristic tumor-infiltrating lymphocyte infiltration patterns. Further clinical validation of anti-PD-L1/PD-1 targeting in selected mucinous ovarian cancers appears promising.

Keyphrases

low grade
poor prognosis
high grade
dna damage
cell cycle
cancer therapy
drug delivery
peripheral blood
long non coding rna
stem cells
cell proliferation
mesenchymal stem cells
anti inflammatory